UFP Technologies (UFPT) investor relations material

Executive summary

• Q2 2026 net sales reached a record $174.0 million, up 15.1% year-over-year, with broad-based MedTech growth and net income of $20.9 million, up 21.4% from Q2 2025.

• Year-to-date net sales were $328.2 million, a 9.6% increase, with net income of $38.3 million, up 11.6% compared to the same period in 2025.

• Growth was diversified across customers and products, with top five customers up 14.7% and the rest of MedTech up 19.7%; non-medical business remained flat.

• Investments in the Dominican Republic and organizational capacity are supporting future growth, though near-term margin pressure exists in U.S. operations.

• CEO transition and leadership strengthening occurred, with related non-cash equity compensation costs.

Financial highlights

• Q2 2026 sales increased 15.1% to $174.0 million; organic sales growth was 12.4%.

• Gross margin improved to 29.3% in Q2 2026 from 28.8% in Q2 2025.

• Adjusted EPS reached a record $2.92 in Q2 2026, up 16.8% year-over-year; six-month diluted EPS was $4.92.

• SG&A expenses increased to $22.8 million in Q2 2026, mainly due to wage, benefit, and CEO transition costs.

• Cash from operations was $15.6 million in Q2; cash and cash equivalents stood at $9.0 million as of June 30, 2026.

Outlook and guidance

• Organic growth is expected to return to the long-term target range of 6%-9% for the remainder of the year, after a strong Q2.

• Management plans to add manufacturing capacity and pursue disciplined acquisitions to support growth.

• Existing resources and revolving credit facility are expected to be sufficient to fund requirements over the next twelve months.

• Fundamentals of served markets remain attractive, with a focus on long-term value creation.

• No formal guidance provided, but double-digit organic growth seen in Q2 is not expected to persist.